MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment
Metrics: PDF 798 views | HTML 1651 views | ?
Jun Yang1, Chengde Liao1, Yifan Liu1, Guangjun Yang1, Tengfei Ke1, Yingying Ding1 and Qinqing Li1
1Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming 650118, Yunnan, P.R. China
Qinqing Li, email: firstname.lastname@example.org
Keywords: anti-angiogenic therapy; vascular normalization window; glioma; DCE-MRI; IVIM-MRI
Received: August 18, 2017 Accepted: October 28, 2017 Published: November 21, 2017
The beginning and the end of the vascular normalization window are not clear in response to anti-angiogenic therapies. We used dynamic contrast-enhanced MRI (DCE-MRI) and intravoxel incoherent motion MRI (IVIM-MRI) to noninvasively evaluate the vascular normalization window. MRI was performed five times: before treatment and on the second, fourth, sixth and eighth days of treatment. Quantitative perfusion parameters were calculated at each time point, including the volume transfer coefficient (Ktrans), reverse transfer constant (Kep), pseudodiffusion coefficient (D*) and perfusion fraction (f). Tumors were evaluated for changes by immunohistochemistry. An increase in Ktrans and Kep was observed after bevacizumab treatment on days 2 and 4. Similar trends were observed for D* and f on days 2 and 4. However, the parameters of Ktrans, Kep, D* and f were decreased on days 6 and 8. A significant increase of the vessel maturity index between the treatment and control groups was measured on days 2 and 4, but this increase abated by days 6 and 8. IVIM and DCE-MRI are helpful when quantifying the tumor perfusion and evaluating the vascular normalization window after anti-vessel therapy. IVIM and DCE-MRI can outline the important period after anti-vessel treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.